NASDAQ / LIVE COMPANY INTELLIGENCE

Lexeo Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERLXEO
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / LXEO COVERAGE

What’s moving Lexeo Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.06%

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.06%

Investors are testing whether Lexeo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?

Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?

Investors are testing whether Lexeo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The story matters when it changes Lexeo Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock

What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock

Investors are testing whether Lexeo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Lexeo Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell

Lexeo Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell

Investors are testing whether Lexeo Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest LXEO filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-11 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-05 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-30 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-25SEC ↗8-KMaterial company eventFiled 2026-06-15 · Period 2026-06-15SEC ↗8-KMaterial company eventFiled 2026-05-11 · Period 2026-05-11SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-30 · Period 2025-12-31SEC ↗4Official SEC filingFiled 2026-07-01 · Period 2026-06-29SEC ↗
EARNINGS / QUARTERLY TRACKER

Lexeo Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.